Amyloid beta (Pyroglutamated/pGlu) Peptide antibody

Details for Product No. ABIN459385
Request Want additional data for this product?

The Independent Validation Initiative strives to provide you with high quality data. Find out more

Antigen
Reactivity
Human, Mouse (Murine)
(1), (1)
Host
Mouse
(1)
Clonality (Clone)
Monoclonal ()
Application
Immunohistochemistry (IHC), ELISA, Western Blotting (WB)
(1), (1), (1)
Pubmed 5 references available
Quantity 100 µL
Shipping to United States (Change)
Availability Will be delivered in 2 to 3 Business Days
Request Want additional data for this product?

The Independent Validation Initiative strives to provide you with high quality data. Find out more

Catalog No. ABIN459385
357.50 $
Plus shipping costs $45.00

Order hotline:

  • +1 404 474 4654
  • +1 888 205 9894 (TF)
Immunogen (3-8) N-terminal pyroglutamated synthetic amyloid beta peptide conjugated with a carrier protein.
Clone 2G6
Isotype IgG1
Specificity Based on amino acid sequence homology, reactivity with most vertebrates including dog, pig, and chicken is expected.
Characteristics Mouse monoclonal antibody against pyroglutamated amyloid beta (pGlu amyloid beta antibody)
Background Aβ pE3 (N-terminally truncated Aβ starting with pyroglutamate) represents a dominant fraction of Aβ peptides in senile plaques of AD brains. Aβ pE3 has higher aggregation propensity and shows increased toxicity compared to full-length Aβ. Intraneuronal accumulation of Aβ pE3 peptides induces severe neuron loss and an associated neurological phenotype. In APP/PS1KI mice, a continuous increase in Aβ pE3 plaque load with increasing age has been reported. It has been suggested that the peptides starting with position 1 of Aβ are N-truncated as disease progresses and that Aβ pE3 positive plaques are resistant to degradation likely due to their high stability and propensity to aggregate (1-5) .
Research Area Alzheimer's Disease
Application Notes IHC, ELISA, Western blotting. Immunohistochemistry: Tissue sections: (alcohol-fixed, paraffin embedded, frozen). Recommended antibody dilution - 1:100 -1:500. Tissue pretreatment with citrate buffer pH 6.0 (microwave boiling for 1-2 min), followed by a 3 minute incubation with 88% formic acid at RT. Western blotting: 1:1000-1:2000 ELISA : 1 : 2000 – 1 : 4000 Optimal dilutions for specific application should be determined by investigator. Appropriate concentration will be affected by several factors, including secondary antibody affinity, antigen concentration, sensitivity of detection method, temperature, length of incubation, etc.: Research Use Only.
Restrictions For Research Use only
Format Liquid
Concentration 2.5 mg/mL
Storage -20 °C
Supplier Images
anti-Amyloid beta (Pyroglutamated/pGlu) Peptide antibody Immunolabelling of senile plaques in cortex from 17 month-old triple-transgenic AD mouse. Antibody dilution 1 : 100
anti-Amyloid beta (Pyroglutamated/pGlu) Peptide antibody (2) Lane 1 – 1 μg of synthetic pGlu 3-42 Aβ peptide per lane, Lane 2 – 5 μg of synthetic 1-42 Aβ peptide per lane
General Tekirian, Saido, Markesbery et al.: "N-terminal heterogeneity of parenchymal and cerebrovascular Abeta deposits." in: Journal of neuropathology and experimental neurology, Vol. 57, Issue 1, pp. 76-94, 1998 (PubMed).

Russo, Violani, Salis et al.: "Pyroglutamate-modified amyloid beta-peptides--AbetaN3(pE)--strongly affect cultured neuron and astrocyte survival." in: Journal of neurochemistry, Vol. 82, Issue 6, pp. 1480-9, 2002 (PubMed).

Revesz, Holton, Lashley et al.: "Genetics and molecular pathogenesis of sporadic and hereditary cerebral amyloid angiopathies." in: Acta neuropathologica, Vol. 118, Issue 1, pp. 115-30, 2009 (PubMed).

Wirths, Breyhan, Cynis et al.: "Intraneuronal pyroglutamate-Abeta 3-42 triggers neurodegeneration and lethal neurological deficits in a transgenic mouse model." in: Acta neuropathologica, Vol. 118, Issue 4, pp. 487-96, 2009 (PubMed).

Wirths O, Bethge T, Marcello A et al.: "Pyroglutamate Abeta pathology in APP/PS1KI mice, sporadic and familial Alzheimer's disease cases" in: J Neural Transm, Vol. 57, Issue 1, pp. 85-96, 2010 (PubMed).

Validation Images
back to top